natgillin/translations-raw huggingface dataset:
A single dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (creatinine clearance (CrCl) using the Cockcroft-Gault formula): mild (CrCl = > 50 to ≤ 80 mL/min), moderate (CrCl = ≥ 30 to ≤ 50 mL/min), severe (CrCl = < 30 mL/min) and end-stage renal disease on haemodialysis.
Enkratni odmerek 50 mg alogliptina so prejele 4 skupine bolnikov z različno stopnjo okvare ledvic (kreatininski očistek (CrCl) po enačbi Cockcroft-Gault): blaga (CrCl = > 50 do ≤ 80 ml/min), zmerna (CrCl = ≥ 30 do ≤ 50 ml/min), huda (CrCl = <30 ml/min) in končna ledvična odpoved na hemodializi.
A single dose of 50 mg of dolutegravir was administered to 8 subjects with moderate hepatic impairment (Child-Pugh class B) and to 8 matched healthy adult controls.
Osem preiskovancev z zmerno okvaro jeter (Child- Pugh B) in 8 usklajenih zdravih odraslih primerjalnih oseb, je prejelo enkratni odmerek 50 mg dolutegravirja.
A single dose of 6 mg gamithromycin/kg body weight (equivalent to 1 ml/25 kg body weight) into the neck.
En odmerek s 6 mg gamitromicina/kg telesne teže (kar ustreza 1 ml/25 kg telesne teže) v področje vratu.
A single dose of Aclasta should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).
Posamezen odmerek zdravila Aclasta ne sme presegati 5 mg, infuzija pa mora trajati najmanj 15 minut (glejte poglavje 4.2).
A single dose of aprepitant 200 mg on Day 1 co-administered with midazolam, a sensitive CYP3A4 substrate, on Days 1, 4 and 8 resulted in a 35 % reduction of midazolam AUC0-∞ on Day 8.
Uporaba enkratnega odmerka aprepitanta 200 mg 1. dan skupaj z midazolamom, občutljivim substratom CYP3A4, prvi, 4. in 8. dan je povzročila 35 % zmanjšanje vrednosti AUC0- midazolama 8. dan.
A single dose of the product should be administered.
Zadostuje enkratni odmerek zdravila.
A single dose of the product should be administered.
Zadostuje enkratni odmerek.
A single dose of the product should be administered.
Zdravilo dajemo v enkratnem odmereku.
A single dose of the product should be administered.
Zdravilo dajemo v enkratnem odmerku.
A single dose of the veterinary medicinal product should be administered.
Zadostuje enkraten odmerek zdravila za uporabo v veterinarski medicini.
A single dose of vaccine orally from 18 days of age.
Enkratni odmerek cepiva, peroralno, od starosti 18 dni.
A single dose of Versican Plus DHPPi should be given every 3 years.
Enkratni odmerek Versican Plus DHPPi je treba dati vsaka 3 leta.
A single dose of Versican Plus DHPPi/L4 should be given every 3 years.
Enkratni odmerek Versican Plus DHPPi/L4 je treba dati vsaka 3 leta.
A single dose of Versican Plus DHPPiL4R should be given every 3 years.
Enkratni odmerek Versican Plus DHPPi/L4R je treba dati vsaka 3 leta.
A single dose of Versican Plus L4 to be given annually.
Enkratni odmerek cepiva Versican Plus L4 letno.
A single dose of Versican Plus Pi to be given annually.
Enkratni odmerek Versican Plus Pi letno.
A single dose of Versican Plus Pi/L4R should be given every 3 years.
Enkratni odmerek Versican Plus Pi/L4R je treba dati vsaka 3 leta.
A single dose of Versican Plus PiL4R should be given every 3 years.
Enkratni odmerek Versican Plus Pi/L4R je treba dati vsaka 3 leta.
A single dose of zoledronic acid should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).
Posamezen odmerek zoledronske kisline ne sme presegati 5 mg, infuzija pa mora trajati najmanj 15 minut (glejte poglavje 4.2).
A single dose of Zoledronic acid Teva Generics should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).
Posamezen odmerek zoledronske kisline ne sme presegati 5 mg, infuzija pa mora trajati najmanj 15 minut (glejte poglavje 4.2).
A single dose of Zoledronic acid Teva Pharma should not exceed 5 mg and the duration of infusion should be at least 15 minutes (see section 4.2).
Posamezen odmerek zdravila Zoledronska kislina Teva Pharma ne sme presegati 5 mg, infuzija pa mora trajati najmanj 15 minut (glejte poglavje 4.2).
A single dose should be administered.
Zdravilo dajemo v enkratnem odmerku.
A single dose, double blind, crossover, randomised trial in 59 healthy males compared the effects on the QT interval of vardenafil (10 mg and 80 mg), sildenafil (50 mg and 400 mg) and placebo.
V dvojno slepi, navzkrižni študiji z enkratnim odmerkom zdravila, v kateri je sodelovalo 59 naključno izbranih zdravih moških, so primerjali učinke enkratnega odmerka vardenafila (10 mg in 80 mg), sildenafila (50 mg in 400 mg) in placeba na dobo QT.
A single Humira pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days.
Posamezen napolnjen injekcijski peresnik zdravila Humira se lahko shranjuje pri temperaturi največ do 25ºC za obdobje do 14 dni.
A single Humira pre-filled syringe may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days.
Posamezna napolnjena injekcijska brizga zdravila Humira se lahko shranjuje pri temperaturi največ do 25ºC za obdobje do 14 dni.
A single injection should be given 2–3 weeks prior to each subsequent mating (approximately every 6 months).
Eno injekcijo je treba dati 2–3 tedne pred vsakim naslednjim parjenjem (približno vsakih 6 mesecev).
A single intramuscular injection (1ml) to pigs from the age of 4 days.
Ena intramuskularna injekcija (1-ml) za prašičke, stare več kot 4 dni.
A single intramuscular injection of 2.5 mg tulathromycin/kg bodyweight (equivalent to 1 ml/10 kg bodyweight) in the neck.
Enkratna intramuskularna aplikacija tulatromicina v odmerku 2,5 mg/kg telesne teže (kar ustreza 1 ml na 10 kg telesne teže) na področje vratu.
A single intramuscular injection of 2.5 mg tulathromycin/kg bodyweight (equivalent to 1 ml/40 kg bodyweight) in the neck.
Enkratna intramuskularna aplikacija tulatromicina v odmerku 2,5 mg/kg telesne teže (kar ustreza 1 ml na 40 kg telesne teže) na področje vratu.
A single intraruminal device is to be administered to a dairy cow/heifer 3-4 weeks prior to expected calving, using an appropriate administration tool.
Z ustreznim orodjem za dajanje dajte kravi molznici/telici en intraruminalni sistem 3–4 tedne pred pričakovano telitvijo.
A single IONSYS system provided a sufficient number of doses for 99% of the studied patients over 24 hours.
En sistem IONSYS je v 24 urah zagotovil zadostno število odmerkov za 99 % preučevanih bolnikov.
A single ivacaftor-treated patient (2.5%) in this age range had an elevation of ALT and AST >8 x ULN.
En sam bolnik v tej starostni skupini (2,5 %), zdravljen z ivakaftorjem, je imel zvišanje ALT in AST > 8 x ULN.
A single oral dose of 2000 mg/kg was lethal in mice and symptoms of toxicity in affected mice included decreased locomotor activity, staggering gait, tremor and hypothermia.
Enkratni peroralni odmerek 2000 mg/kg je bil smrten pri miših, simptomi toksičnosti pri prizadetih miših pa so vključevali zmanjšano lokomotorno aktivnost, nestabilno gibanje, tremor in hipotermijo.
A single oral dose of 40 mg osaterone acetate in human males was followed by a sporadic decrease in FSH, LH and testosterone, reversible after 16 days.
Enkraten peroralno zaužiti odmerek 40 mg osateronijevega acetata pri moških je v posameznih primerih povzročil znižanje koncentracije FSH, LH in testosterona, ki se je vrnila v običajno po 16 dneh.
A single subcutaneous administration of Repatha 140 mg or 420 mg resulted in maximum suppression of circulating unbound PCSK9 by 4 hours followed by a reduction in LDL-C reaching a mean nadir in response by 14 and 21 days, respectively.
Enkratna subkutana injekcija zdravila Repatha 140 mg ali 420 mg je dosegla največjo supresijo nevezanega PCSK9 v obtoku v 4 urah, sledilo je znižanje LDL-H z doseženo povprečno najnižjo vrednostjo po 14 dneh (140 mg odmerek) oziroma 21 dneh (420 mg odmerek).
A single subcutaneous administration of Repatha 140 mg or 420 mg resulted in maximum suppression of circulating unbound PCSK9 by 4 hours followed by a reduction in LDL-C reaching a mean nadir in response by 14 and 21 days, respectively.
Enkratna subkutana injekcija zdravila Repatha 140 mg ali 420 mg je dosegla največjo supresijo nevezanega PCSK9 v obtoku v 4 urah, sledilo je znižanje LDL-H z doseženo povprečno najnižjo vrednostjo po 14 dneh (149 mg odmerek) oziroma 21 dneh (420 mg odmerek).
A single subcutaneous injection of 2.5 mg tulathromycin/kg bodyweight (equivalent to 1 ml/40 kg bodyweight).
Enkratna podkožna aplikacija tulatromicina v odmerku 2,5 mg/kg telesne teže (kar ustreza 1 ml na 40 kg telesne teže).
A single topical application provides pain relief for at least 4 days.
En topikalni nanos lajša bolečine najmanj 4 dni.
A single treatment is effective for the treatment of gastrointestinal nematodes.
Pri nematodih v prebavilih zadostuje že en cikel zdravljenja.
a single unit pack with 1 vial containing 1g of powder (3.3 mg eptotermin alfa) and 1 vial containing 230 mg carmellose powder
pakiranje z eno enoto vsebuje 1 vialo z 1 g praška (3,3 mg eptotermina alfa) in 1 vialo z 230 mg karmeloznega praška
A single vaccination with Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) induced high and rapid serological response in subjects primed 6-8 years previously with two doses of a different surrogate H5N vaccine, having same formulation as Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics but using the strain H5N3.
Eno cepljenjem s cepivom Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics (H5N1, A/Vietnam/1194/2004) je povzročilo visok in hiter serološki odziv pri osebah, ki so bile 6–8 let pred tem primarno imunizirane z dvema odmerkoma različnih nadomestnih cepiv za H5N, z enako formulacijo kot cepivo Prepandemic Influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics, a s sevom H5N3.
A single ‘booster’ injection should be given every year to maintain the vaccine’s effect.
Za vzdrževanje učinka cepiva je treba nato vsako leto psu injicirati enkratni obnovitveni odmerek.
A single, randomised, multi-center, controlled phase 2 trial of belatacept in de novo orthotopic liver transplant recipients was conducted.
Izvedeno je bilo eno samo randomizirano, multicentrično, nadzorovano preskušanje 2. faze belatacepta pri bolnikih z na novo presajenimi jetri.
A single-arm, multicentre study (N  146) of vemurafenib was conducted in adult patients with histologically confirmed metastatic melanoma harbouring the BRAF V600 mutation (according to the cobas 4800 BRAF V600 Mutation Test) and with brain metastases.
Multicentrična študija z enim krakom (n  146), v kateri so preskušali vemurafenib, je bila izvedena pri odraslih bolnikih s histološko potrjenim metastatskim melanomom z mutacijo BRAF V600 (glede na cobas 4800 BRAF V600 Mutation Test) in zasevki v možganih.
A single-arm, Phase 1/2 open-label, multicenter trial was conducted to evaluate the efficacy and safety of Bosulif 500 mg once daily in patients with imatinib-resistant or -intolerant CML with separate cohorts for chronic, accelerated, and blast phase disease previously treated with one prior tyrosine kinase inhibitor (TKI) (imatinib) or more than one TKI (imatinib followed by dasatinib and/or nilotinib).
Izvedli so enoskupinsko, odprto, multicentrično preskušanje 1./2. faze, v katerem so ocenjevali učinkovitost in varnost zdravila Bosulif 500 mg enkrat na dan pri bolnikih s KML, ki so na imatinib neodzivni ali ga niso prenašali; preskušanje je imelo ločene kohorte za kronično, pospešeno ali blastno fazo; bolniki so bili predhodno zdravljeni z enim zaviralcem tirozinske kinaze (TKI - tyrosine kinase inhibitor) (imatinib) ali več kot enim TKI (imatinib, ki mu je sledil dasatinib in/ali nilotinib).
A single-dose drug-drug interaction study in healthy volunteers with 25 mg warfarin, a sensitive CYP2C9 substrate, and 800 mg nilotinib did not result in any changes in warfarin pharmacokinetic parameters or warfarin pharmacodynamics measured as prothrombin time (PT) and international normalised ratio (INR).
V eni sami študiji medsebojnega delovanja med dvema zdraviloma, v katero so vključili zdrave prostovoljce, sočasna uporaba 25 mg varfarina, občutljivega substrata CYP2C9, in 800 mg nilotiniba ni povzročila nobenih sprememb farmakokinetike ali farmakodinamike varfarina, kar so ugotavljali z merjenjem protrombinskega časa in mednarodno umerjenega razmerja protrombinskega časa (international normalised ratio – INR).
A single-dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (creatinine clearance (CrCl) using the Cockcroft-Gault formula): mild (CrCl = > 50 to ≤ 80 mL/min), moderate (CrCl = ≥ 30 to ≤ 50 mL/min), severe (CrCl = < 30 mL/min) and end-stage renal disease on haemodialysis.
Enkratni odmerek 50 mg alogliptina so prejele 4 skupine bolnikov z različno stopnjo okvare ledvic (kreatininski očistek (CrCl) po enačbi Cockcroft-Gault): blaga (CrCl = > 50 do ≤ 80 ml/min), zmerna (CrCl = ≥ 30 do ≤ 50 ml/min), huda (CrCl = <30 ml/min) in končna ledvična odpoved na hemodializi.
A single-dose study in healthy subjects and subjects with various degrees of renal impairment (mild, moderate, and severe renal impairment as well as subjects with end state renal disease) showed a fractional increase in AUC (13-62%) and Cmax (42-71%) in subjects with mild (estimated glomerular filtration rate 50 to ≤80 mL/min/1.73m2), moderate (estimated glomerular filtration rate 30 to 50 mL/min/1.73m2), and severe (estimated glomerular filtration rate <30 mL/min/1.73m2) renal impairment, compared to subjects with normal renal function (estimated glomerular filtration rate >80 mL/min/1.73m2).
Študija z enim odmerkom pri zdravih osebah in osebah z različnimi stopnjami ledvične okvare (blaga, zmerna in huda ledvična okvara ter pri osebah s končno ledvično odpovedjo) je pokazala frakcijsko povišanje AUC (13–62 %) in Cmax (42–71 %) pri osebah z blago (ocenjena stopnja glomerulne filtracije 50 do ≤ 80 ml/min/1,73m2), zmerno (ocenjena stopnja glomerulne filtracije 30 do  50 ml/min/1,73m2) in hudo (ocenjena stopnja glomerulne filtracije < 30 ml/min/1,73m2) ledvično okvaro, v primerjavi z osebami z normalnim delovanjem ledvic (ocenjena stopnja glomerulne filtracije > 80 ml/min/1,73m2).
A single-dose study in subjects with varying degrees of liver cirrhosis (Child-Pugh Classes A, B, and
Raziskava z enim samim odmerkom pri preiskovancih z različno stopnjo jetrne ciroze (razredi A, B in C po Child-Pughu) ni pokazala pomembnega učinka okvare jeter na farmakokinetiko aripiprazola in dehidroaripiprazola.
A single-dose, open-label study was conducted to evaluate the pharmacokinetics of a 10 mg oral dose of saxagliptin in subjects with varying degrees of chronic renal impairment compared to subjects with normal renal function.
Za primerjalno oceno farmakokinetike 10-mg peroralnega odmerka saksagliptina pri preiskovancih z različno stopnjo kronične okvare ledvic in pri preiskovancih z normalnim delovanjem ledvic je bila narejena odprta študija z enkratnim odmerkom.
A single-dose, open-label study was conducted to evaluate the pharmacokinetics of a 10 mg oral dose of saxagliptin in subjects with varying degrees of chronic renal impairment compared to subjects with normal renal function.
Za primerjalno oceno farmakokinetike 10-mg peroralnega odmerka saksagliptina pri preiskovancih z različno stopnjo kronične okvare ledvic in pri preiskovancih z normalnim delovanjem ledvic je bila opravljena odprta študija s posamičnim odmerkom.
A single-dose, open-label study was conducted to evaluate the pharmacokinetics of a reduced dose of sitagliptin (50 mg) in patients with varying degrees of chronic renal impairment compared to normal healthy control subjects.
Izvedena je bila odprta študija z enim samim odmerkom, v kateri so ovrednotili farmakokinetiko zmanjšanega odmerka sitagliptina (50 mg) pri bolnikih z različnimi stopnjami kronične ledvične okvare v primerjavi z zdravimi kontrolnimi osebami.
A single-use pre-filled pen contains one 50 mg dose of Benepali.
Napolnjen injekcijski peresnik za enkratno uporabo vsebuje en 50-mg odmerek zdravila Benepali.
A single-use sachet is sufficient to cover a wart area of 20 cm2 (approx.
Vrečka za enkratno uporabo zadostuje za prekritje 20 cm2 področja z bradavicami.
A sixth study (PALLAS) compared Multaq with placebo in patients over 65 years of age with permanent atrial fibrillation and several risk factors.
V šesti študiji (PALLAS) so zdravilo Multaq primerjali s placebom pri bolnikih, starejših od 65 let, s permanentno atrijsko fibrilacijo in številnimi dejavniki tveganja.
A sixth study in 508 adult patients looked at the number of patients whose symptoms improved and who did not need additional treatment with corticosteroids (other medicines used in Crohn’s disease).
Šesta študija je pri 508 odraslih bolnikih beležila število bolnikov, pri katerih so se simptomi izboljšali in ki niso potrebovali dodatnega zdravljenja s kortikosteroidi (drugimi zdravili za zdravljenje Chronove bolezni).
A sixth study looked at the effectiveness of TachoSil in surgery on the heart or major blood vessels.
V šesti študiji so merili učinkovitost zdravila TachoSil pri kirurških posegih na srcu in glavnih krvnih žilah.
A sixth study showed that after 24 weeks of treatment, patients taking dapagliflozin plus metformin had an average reduction in body weight of around 2 kg more than those taking placebo plus metformin.
Šesta študija pa je pokazala, da se je po 24 tednih zdravljenja pri bolnikih, ki so jemali dapagliflozin skupaj z metforminom, telesna masa v povprečju zmanjšala za približno 2 kg več kot pri bolnikih, ki so jemali placebo in metformin.
A skeletal-related event was defined as radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain.
Z okostjem povezan dogodek je bil opredeljen kot obsevanje ali operacija kosti, patološki zlom kosti, kompresija hrbtnega mozga ali sprememba antineoplastičnega zdravljenja za zdravljenje kostnih bolečin.
a skin growth called a ‘benign skin neoplasm’
rast kože imenovana benigna neoplazma kože,
a skin growth called a ‘benign skin neoplasm’
rast kože imenovana »benigna neoplazma kože
a skin growth called a ‘benign skin neoplasm’
rast kože, imenovana benigna neoplazma kože,
a skin growth called a ‘benign skin neoplasm”
rast kože, imenovana benigna neoplazma kože,
a skin growth called a ‘“benign skin neoplasm”’
rast kože, imenovana benigna neoplazma kože;
a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme) a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome)
kožni izpuščaj, ki lahko tvori mehurčke in po videzu spominja na majhne tarče (na sredini temne pike, obkrožene s svetlejšim delom in s temnim krogom na robu) (multiformni eritem) široko razširjen izpuščaj z mehurčki in luščenjem kože, še posebej okoli ust, nosu, oči in v predelu spolovil (Stevens-Johnsonov sindrom)
a skin reaction on the palms of the hands or soles of the feet (including tingling, numbness, pain, swelling or reddening)
kožna reakcija na dlaneh ali stopalih (vključno z zbadanjem, odrevenelostjo, bolečino, oteklino ali rdečino),
A slight black deposit may appear and the emulsion may separate into two distinct phases during storage.
Med shranjevanjem se lahko pojavi rahla črna usedlina in emulzija se lahko razsloji v dve fazi.
a slight decrease in the number of white blood cells (leucopenia),
rahlo zmanjšanje števila belih krvnih celic (levkopenija),
A slight increase in creatinine values compared to baseline was observed in the imepitoin-treated dogs.
Rahlo zvišanje vrednosti kreatinina v primerjavi z izhodiščem so opazili pri psih, zdravljenih z imepitoinom.
A slight increase in incidence of supernumerary ribs was observed in rat pups of dams exposed to raltegravir at approximately 4.4-fold human exposure at 400 mg twice daily based on AUC0-24 hr.
Pri mladičih podgan, ki so bile izpostavljene raltegravirju v količini, ki je bila glede na AUC0-24 ur približno 4,4-kratna izpostavljenost kot pri človeku, ki prejema 400 mg dvakrat na dan, so opazili nekoliko večjo pojavnost prekomernega števila reber.
A slight increase in incidence of supernumerary ribs was observed in rat pups of dams exposed to raltegravir at approximately 4.4-fold human exposure at 400 mg twice daily based on AUC0-24 hr.
Pri mladičih podgan, ki so bile izpostavljene raltegravirju v količini, ki je bila glede na AUC0-24ur približno 4,4-krat tolikšna kot izpostavljenost pri človeku med uporabo 400 mg dvakrat na dan, so opazili nekoliko večjo pojavnost prekomernega števila reber.
A slight increase in the incidence of uterine leiomyomas has been observed in rats and mice; an effect which is considered to be a class- effect in rodents after long-term exposure to high doses of β2-adrenoreceptor agonists.
Pri podganah in miših so opazili rahlo povečanje pogostosti leiomiomatoze maternice, učinek, ki naj bi bil učinek razreda pri glodavcih po dolgotrajni izpostavljenosti agonistom β2-adrenergičnih receptorjev.
A slight increase in the incidence of uterine leiomyomas has been observed in rats and mice; an effect which is considered to be a class-effect in rodents after long-term exposure to high doses of β2-adrenoreceptor agonists.
Pri podganah in miših so opazili rahlo povečanje pogostosti leiomiomatoze maternice, učinek, ki naj bi bil učinek razreda pri glodavcih po dolgotrajni izpostavljenosti agonistom β2-adrenergičnih receptorjev.
A slight increase in the occurrence of blood clots has been observed.
Opazili so rahel porast v pojavu krvnih strdkov.
A slight temporary swelling at the injection site following injection under the skin was observed in cattle.
Pri govedu so opazili blago prehodno oteklino na mestu injiciranja v podkožje.
A slight to moderate reduction in spermatogenesis was also observed in the dog at oral doses  30 mg/kg.
Pri psu so pri peroralnih odmerkih ≥ 30 mg/kg opazili tudi rahlo do zmerno zmanjšanje spermatogeneze.
A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
V kliničnih raziskavah so pri manj kot 10 % goveda zasledili samo blago in prehodno oteklino na mestu podkožne injekcije.
A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
V kliničnih raziskavah so zasledili blago in prehodno oteklino na mestu injiciranja po subkutanem dajanju, in sicer pri manj kot 10 % goved.
A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
V kliničnih raziskavah so zasledili blago in prehodno oteklino na mestu injiciranja po subkutanem dajanju, in sicer pri manj kot 10 % goveda.
A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
V kliničnih raziskavah so zasledili blago in prehodno oteklino na mestu podkožne injekcije, in sicer pri manj kot 10 % goveda.
A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10 % of the cattle treated in clinical studies.
V kliničnih raziskavah so zasledili samo blago in prehodno oteklino na mestu podkožne injekcije, in sicer pri manj kot 10 % goveda.
A slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies.
V kliničnih raziskavah so zasledili blago in prehodno oteklino na mestu podkožne injekcije in sicer pri manj kot 10 % goveda.
A slightly viscous clear, colourless to yellow-brown liquid.
Rahlo viskozna, bistra tekočina brezbarvne do rumeno-rjave barve.